赛升药业：取得换发《药品生产许可证》

Core Viewpoint - Recently, the company received a renewed Drug Production License from the Beijing Drug Administration, which is valid until November 4, 2030, ensuring the continuity of its production operations without significant impact on its performance [1] Group 1 - The renewal of the Drug Production License was prompted by the impending expiration of the original license [1] - The new license acquisition guarantees the company's normal production and business operations [1] - The company does not anticipate any major impact on its financial performance due to this renewal [1]